CONSTITUENT REPORT
Isoamyl angelate
Isoamyl angelate is an angelic-acid ester strongly associated with Roman chamomile essential oil. The live evidence base is strongest for identity, repeated occurrence in Roman chamomile chemotypes, and one preclinical behavior study that tested the isolated constituent in mice. That makes isoamyl angelate more than a trace registry entry, but the evidence still sits well below human clinical or constituent-specific toxicology depth, so AromaForge should keep it framed as a chamomile marker ester with limited preclinical activity data.
Aroma and practical use
- Use the recorded fruity, wine-like, herbaceous, fresh, chamomile-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Compare the recorded goal signals with the intended purpose, while keeping model assumptions separate from observed study outcomes.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
The EMA Roman chamomile assessment reports isoamyl angelate at 5.3-17.9% in flower oil, placing it among the characteristic esters of the oil.
The EMA Roman chamomile assessment reports isoamyl angelate at 5.3-17.9% in flower oil, placing it among the characteristic esters of the oil.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2022 Roman chamomile valorization study reported isoamyl angelate at 5.57-9.02% across vegetation phases, showing that abundance shifts with harvest stage.
A 2022 Roman chamomile valorization study reported isoamyl angelate at 5.57-9.02% across vegetation phases, showing that abundance shifts with harvest stage.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2024 cultivation study reported isoamyl angelate at 13.8% in one Roman chamomile essential-oil sample grown on calcomelanosol, again supporting its importance as a major ester.
A 2024 cultivation study reported isoamyl angelate at 13.8% in one Roman chamomile essential-oil sample grown on calcomelanosol, again supporting its importance as a major ester.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2017 Flavour and Fragrance Journal study identified isoamyl angelate as one of the major active constituents in Roman chamomile oil that significantly promoted mouse ambulation.
A 2017 Flavour and Fragrance Journal study identified isoamyl angelate as one of the major active constituents in Roman chamomile oil that significantly promoted mouse ambulation.
This experimental finding does not establish benefit, dose or safety in people using this blend.
The same 2017 study reported that the ambulatory effect was attenuated by chlorpromazine and haloperidol, suggesting dopamine-pathway involvement.
The same 2017 study reported that the ambulatory effect was attenuated by chlorpromazine and haloperidol, suggesting dopamine-pathway involvement.
This experimental finding does not establish benefit, dose or safety in people using this blend.
How it contributes to goal calculations
Model markers guide the formulation score. They are separate from the source findings above.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedTCI lists the isolated material as a combustible liquid with hazard statement H227.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No constituent-specific public dermal maximum or dedicated toxicology monograph suitable for archive limit-setting was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
Isobutyl angelateAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
animal · effect
No source citation attached.
Read Isobutyl angelate report →How the effects were investigated
Likely ester hydrolysis by carboxylesterases
This is a chemistry inference from general ester metabolism rather than a direct isoamyl-angelate metabolism paper.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Possible dopamine-linked behavioral signaling in mice
The mouse ambulation paper reported attenuation by chlorpromazine and haloperidol, which the authors interpreted as evidence of dopamine involvement.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No human clinical study focused on isolated isoamyl angelate was verified in this pass.
- Constituent-specific dermal safety limits were not located.
- Metabolic handling is inferred from general ester biology rather than direct isoamyl-angelate testing.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.